A 58-year-old woman with coronary artery disease and an LDL cholesterol of 95 mg/dL on atorvastatin 40 mg daily presents for lipid management optimization. Her cardiologist recommends further LDL reduction to <70 mg/dL. Which drug should be added to achieve this goal?

Explanation

## Adjunctive Therapy for LDL Reduction in CAD Patients **Key Point:** When a patient on statin monotherapy has not achieved LDL-C goal (<70 mg/dL in CAD), the preferred second-line agent is ezetimibe, which works synergistically with statins via a different mechanism and provides an additional 15–20% LDL reduction. ### Mechanism of Ezetimibe Ezetimibe inhibits cholesterol absorption in the small intestine (Niemann-Pick C1-like 1 transporter), reducing intestinal cholesterol delivery to the liver. This: - Lowers LDL-C by 15–20% when added to statin - Does NOT inhibit HMG-CoA reductase (different mechanism from statins) - Allows synergistic LDL reduction without increasing myositis risk - Is well-tolerated with minimal drug interactions **High-Yield:** Ezetimibe + statin combination is recommended by ACC/AHA and ESC guidelines as the preferred second-line approach for patients not at LDL goal on statin monotherapy. ### Rationale for Ezetimibe Over Alternatives | Agent | Mechanism | LDL ↓ | Evidence | Role | |-------|-----------|-------|----------|------| | **Ezetimibe** | Cholesterol absorption inhibitor | +15–20% | Strong (IMPROVE-IT) | **2nd-line adjunct** | | Rosuvastatin | HMG-CoA reductase inhibitor | +10–20% more | Good | Statin intensification | | Fenofibrate | PPAR-α agonist | Minimal | Weak for LDL | TG-focused | | Bempedoic acid | AMPK activator | +10–15% | Emerging | 3rd/4th-line | **Clinical Pearl:** The IMPROVE-IT trial (2015) demonstrated that ezetimibe added to simvastatin reduced cardiovascular events in post-ACS patients, providing Class 2a evidence for ezetimibe as adjunctive therapy in CAD. ### When to Intensify Statin Instead If the patient is on a moderate-intensity statin (e.g., atorvastatin 40 mg), uptitration to high-intensity statin (atorvastatin 80 mg or rosuvastatin 20–40 mg) is an alternative. However, ezetimibe is preferred as add-on therapy because: - It provides additional LDL reduction without increasing myositis risk - The combination has proven cardiovascular benefit - It is cost-effective **Warning:** Fenofibrate is inappropriate here because it is not effective for LDL reduction and is indicated for hypertriglyceridemia, not LDL-C elevation. Bempedoic acid is a newer agent with limited cardiovascular outcome data and is reserved for statin-intolerant patients or as third-line therapy.